Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.

Tang L, Yang J, Ng SK, Rodriguez N, Choi PW, Vitonis A, Wang K, McLachlan GJ, Caiazzo RJ Jr, Liu BC, Welch WR, Cramer DW, Berkowitz RS, Ng SW.

Eur J Cancer. 2010 Jan;46(1):170-9. doi: 10.1016/j.ejca.2009.10.003.

2.

Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.

Karabudak AA, Hafner J, Shetty V, Chen S, Secord AA, Morse MA, Philip R.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1757-70. doi: 10.1007/s00432-013-1501-6. Epub 2013 Sep 3.

3.

Autoantibody biomarkers for the detection of serous ovarian cancer.

Katchman BA, Chowell D, Wallstrom G, Vitonis AF, LaBaer J, Cramer DW, Anderson KS.

Gynecol Oncol. 2017 Jul;146(1):129-136. doi: 10.1016/j.ygyno.2017.04.005. Epub 2017 Apr 18.

PMID:
28427776
4.

[Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].

Zhao BB, Yang ZJ, Wang Q, Pan ZM, Zhang W, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):11-19. doi: 10.3760/cma.j.issn.0529-567X.2017.01.005. Chinese.

PMID:
28190310
5.

The "reverse capture" autoantibody microarray : an innovative approach to profiling the autoantibody response to tissue-derived native antigens.

Ehrlich JR, Tang L, Caiazzo RJ Jr, Cramer DW, Ng SK, Ng SW, Liu BC.

Methods Mol Biol. 2008;441:175-92. doi: 10.1007/978-1-60327-047-2_12.

PMID:
18370319
6.

Autoantibody biomarker opens a new gateway for cancer diagnosis.

Nesterova M, Johnson N, Cheadle C, Cho-Chung YS.

Biochim Biophys Acta. 2006 Apr;1762(4):398-403. Epub 2006 Jan 30.

7.

Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer.

Kim S, Cho H, Nam EJ, Kim SW, Kim YT, Park YW, Kim BW, Kim JH.

Genes Chromosomes Cancer. 2010 Jul;49(7):585-95. doi: 10.1002/gcc.20769.

PMID:
20461751
8.

Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.

Shi JX, Qin JJ, Ye H, Wang P, Wang KJ, Zhang JY.

Expert Rev Mol Diagn. 2015 Jun;15(6):829-52. doi: 10.1586/14737159.2015.1035713. Epub 2015 May 9. Review.

PMID:
25959246
9.

Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.

Sun H, Shi JX, Zhang HF, Xing MT, Li P, Dai LP, Luo CL, Wang X, Wang P, Ye H, Li LX, Zhang JY.

Tumour Biol. 2017 Jun;39(6):1010428317699132. doi: 10.1177/1010428317699132.

PMID:
28618923
10.

Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.

Ummanni R, Duscharla D, Barett C, Venz S, Schlomm T, Heinzer H, Walther R, Bokemeyer C, Brümmendorf TH, Murthy PV, Balabanov S.

J Proteomics. 2015 Apr 24;119:218-29. doi: 10.1016/j.jprot.2015.02.005. Epub 2015 Feb 24.

PMID:
25724726
11.

Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients.

Chinni SR, Falchetto R, Gercel-Taylor C, Shabanowitz J, Hunt DF, Taylor DD.

Clin Cancer Res. 1997 Sep;3(9):1557-64.

12.

Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.

Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC.

Clin Cancer Res. 2003 Oct 15;9(13):4782-91.

13.

Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.

Marx D, Frey M, Zentgraf H, Adelssen G, Schauer A, Kuhn W, Meden H.

Cancer Detect Prev. 2001;25(2):117-22.

PMID:
11341346
14.

Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.

Taylor DD, Gercel-Taylor C, Parker LP.

Gynecol Oncol. 2009 Oct;115(1):112-20. doi: 10.1016/j.ygyno.2009.06.031. Epub 2009 Jul 31.

15.
16.

[Clinical study of autoantibody spectrum against ovarian cancer associated antigens combined with CA(125) in detecting and monitoring ovarian cancer].

Yang ZJ, Yang G, Jiang YM, Ran YL, Yang ZH, Zhang W, Zhang JQ, Pan ZM, Li L.

Zhonghua Fu Chan Ke Za Zhi. 2011 Feb;46(2):113-8. Chinese.

PMID:
21426769
17.

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.

Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ.

J Exp Med. 1998 Apr 20;187(8):1349-54.

18.

Three novel mouse monoclonal antibodies, OM-A, OM-B, and OM-C, reactive with mucinous type ovarian tumors.

Sakakibara K, Ueda R, Ohta M, Nakashima N, Tomoda Y, Takahashi T.

Cancer Res. 1988 Aug 15;48(16):4639-45.

19.

Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.

Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC.

Clin Cancer Res. 2008 Feb 1;14(3):764-71. doi: 10.1158/1078-0432.CCR-07-0856.

20.

Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.

Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM.

Cancer Immunol Immunother. 2011 Jul;60(7):975-84. doi: 10.1007/s00262-011-1010-x. Epub 2011 Apr 2.

PMID:
21461842

Supplemental Content

Support Center